admin – Page 5603 – Get News Story

Psychiatric Digital Biomarkers Market 2024: Key Trends, Innovations, and Market Outlook

“Psychiatric Digital Biomarkers Market”

Psychiatric Digital Biomarkers Market is estimated to reach over USD 2,879.7 Mn by 2031, exhibiting a CAGR of 24.7% during the forecast period.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Psychiatric Digital Biomarkers Market”-, By Type (Wearable, Mobile based Applications, Sensors) Clinical Practice (Diagnostic Psychiatric Digital Biomarkers, Monitoring Psychiatric Digital Biomarkers, Predictive and Prognostic Psychiatric Digital Biomarkers), End Use (Healthcare companies, Healthcare Providers, Payers), Industry Trends, and Global Forecasts, 2024-2031 And Segment Revenue and Forecast To 2031.”

The Psychiatric Digital Biomarkers Market is estimated to reach over USD 2,879.7 Mn by 2031, exhibiting a CAGR of 24.7% during the forecast period.

Psychiatric digital biomarkers are created by measuring physiological and behavioral data gathered through digital devices such as wearables, smartphones, and other digital platforms, which provide objective and quantitative assessments. These biomarkers enable the evaluation, tracking, and prediction of mental health disorders. Advanced algorithms and machine learning techniques analyze the collected data to identify patterns associated with various mental health conditions. For example, machine learning-based voice analysis is used to derive digital biomarkers of cognitive functioning in trauma survivors, while dynamic tracking of changes in biomarkers helps in monitoring Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, depression, and schizophrenia. Additionally, touch screens, keyboards, and microphones serve as biomarkers for motor control and speech in Alzheimer’s patients, respectively, facilitating a comprehensive approach to understanding and managing mental health conditions.

In March 2022, DTU Health Tech researchers created a technique that uses voice analysis to detect mood swings in patients and diagnose bipolar disorder in individuals, with customized models yielding the most accurate findings.

Get Free Access to Demo Report, Excel Pivot and ToC : https://www.insightaceanalytic.com/request-sample/2637

List of Prominent Players in the Psychiatric Digital Biomarkers Market:

Koneksa
Biogen Inc.
BioSensics
Empatica Inc.
Vivo Sense
IXICO plc
Huma
kintsugi health
Sonde Health, Inc.
Clario
icometrix
iMediSync

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2024-02

Market Dynamics:

Drivers

The rising rates of mental health conditions, such as depression, anxiety, and bipolar disorder, drive the demand for innovative diagnostic and monitoring solutions to manage these disorders effectively. Innovations in wearable technology, mobile applications, sensors, and data analytics have expanded the capabilities of digital biomarkers, making them more accessible and effective for mental health monitoring and management. Increased awareness of mental health issues and the benefits of digital health technologies has led to greater acceptance among patients and healthcare providers, boosting the adoption of digital biomarkers.

Challenges:

Ensuring the protection of sensitive mental health data is crucial. Compliance with data protection regulations, such as GDPR and HIPAA, is required to maintain patient trust and safeguard information from breaches is a significant challenge.

Regional Trends:

North America has the largest market share during the forecast period. The region benefits from well-established regulatory pathways, which facilitate the approval and adoption of new digital health technologies. The widespread use of telehealth and digital health solutions supports the growth of psychiatric digital biomarkers. However, The Asia-Pacific region is an emerging market for psychiatric digital biomarkers, with rapid technological advancements and increasing healthcare expenditure.

Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/enquiry-before-buying/2637

Recent Developments:

In July 2024, have decided to work together on a cutting-edge mental health treatment program. Sonde Health will evaluate users’ mental health daily using its clinically recognized Mental Fitness vocal biomarker technology. In the meantime, the biggest telecom provider in South Korea, KT Corporation, will provide the necessary services and infrastructure to support users in enhancing their mental well-being.
In May 2023, iMediSync, Mila announced a collaboration with iMediSync, a company whose goal is to transform mental health with the application of artificial intelligence (AI) and a data-driven methodology. iMediSync is a global digital mental health firm with headquarters in Korea that specializes on near-infrared light emitting diodes (NIR-LED)-based precision digital treatments and brainwave-centered diagnostics for early screening and prediction of various brain illnesses.

Segmentation of Psychiatric Digital Biomarkers Market.

Global Psychiatric Digital Biomarkers Market – By Type

Wearable
Mobile based Applications
Sensors
Others

Global Psychiatric Digital Biomarkers Market – Clinical Practice

Diagnostic Psychiatric Digital Biomarkers
Monitoring Psychiatric Digital Biomarkers
Predictive and Prognostic Psychiatric Digital Biomarkers
Other’s

Global Psychiatric Digital Biomarkers Market – End Use

Healthcare companies
Healthcare Providers
Payers
Others

Global Psychiatric Digital Biomarkers Market – By Region

North America-

The US
Canada
Mexico

Europe-

Germany
The UK
France
Italy
Spain
Rest of Europe

Asia-Pacific-

China
Japan
India
South Korea
Southeast Asia
Rest of Asia Pacific

Latin America-

Brazil
Argentina
Rest of Latin America

Middle East & Africa-

GCC Countries
South Africa
Rest of the Middle East and Africa

Unlock Your GTM Strategy @ https://www.insightaceanalytic.com/customisation/2637

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Media Contact
Company Name: InsightAce Analytic Pvt. Ltd
Contact Person: Diana D’Souza
Email: Send Email
Country: United States
Website: https://www.insightaceanalytic.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Psychiatric Digital Biomarkers Market 2024: Key Trends, Innovations, and Market Outlook

Obesity Pipeline Drugs 2024 | Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehrin

DelveInsight’s, “Obesity Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Obesity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Obesity pipeline products in this space.

Discover the latest drugs and treatment options in the Obesity Pipeline. Dive into DelveInsight’s comprehensive report today! @ Obesity Pipeline Outlook

Key Takeaways from the Obesity Pipeline Report

August 2024:- Palatin Technologies, Inc- A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Study Investigating the Safety, Tolerability, and Effectiveness of the Co-Administration of Bremelanotide With Tirzepatide (GLP-1/GIP) for the Treatment of Obesity. This is a prospective, randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of bremelanotide (BMT) used in combination with tirzepatide therapy in the treatment of obesity in subjects with a BMI ranging from 30.0 to 45.0 kg/m2 (inclusive).
August 2024:- Novo Nordisk A/S- Efficacy and Safety of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly Compared to Tirzepatide 15 mg s.c. Once-weekly in Participants With Obesity. This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors.
DelveInsight’s Obesity pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Obesity treatment.
The leading Obesity Companies such as Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others.
Promising Obesity Therapies such as APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and others.

Stay ahead with the most recent pipeline outlook for Obesity. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Obesity Treatment Drugs

Obesity Emerging Drugs

Survodutide: Zealand Pharma

Survodutide (BI 456906) is a long-acting glucagon/GLP-1 receptor dual agonist for once-weekly subcutaneous administration that activates two key gut hormone receptors simultaneously and may offer better efficacy than current single-hormone receptor agonist treatments. Survodutide is targeting the treatment of obesity and nonalcoholic steatohepatitis (NASH). Boehringer Ingelheim is advancing survodutide into three global Phase III trials in people living with overweight or obesity.

Ecnoglutide: Sciwind Biosciences

Glucagon-like peptide-1 (GLP-1) analogs are effective therapies in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for NASH. Ecnoglutide (XW003) is a novel, cAMP signaling biased, long-acting GLP-1 analogue optimized for improved biological activity, cost-effective manufacturing, and once weekly dosing. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Obesity.

CT-868: Carmot Therapeutics

CT-868 is a dual GLP-1 and GIP receptor modulator with a unique pharmacological profile optimized for improved tolerability at the GLP-1 receptor. The combined action of GLP-1 and GIP results in greater body weight loss and glucose control. CT-868 is dosed once daily to maximize efficacy and tolerability. CT-868 dual agonist candidate was discovered using the chemotype evolution technology as a peptide-small molecule hybrid compound, able to mimic the native GLP-1 hormone. In the Phase I trial, CT-868 demonstrated compelling pharmacodynamic activity across several clinical measures in overweight and obese healthy individuals a safe and generally well-tolerated profile. Carmot Therapeutics is now expanding the observations in overweight and obese patients with type 2 diabetes to demonstrate CT-868’s effects on glycemic control, weight loss, and tolerability. Currently, the drug is in the Phase II stage of development to treat obesity.

DD01: D&D Pharmatech

DD01 is a proprietary, imbalanced dual agonist of GLP-1 and glucagon receptors with a half-life of 11 days in non-human primates. DD01 is being developed as a potential disease-modifying agent for obesity and liver fatty disease. Treatment with DD01 caused weight loss, reduced liver fat, and improved glucose tolerance in preclinical obesity, diabetes, and fatty liver models. In preclinical models of diabetes and nonalcoholic fatty liver disease (NAFLD), DD01 could reduce weight and blood sugar and improve insulin sensitivity and lipid and fat metabolism, which could ameliorate NASH. DD01 demonstrated greater efficacy in preclinical models than semaglutide, an approved GLP-1R receptor agonist; from a mechanical perspective, the effect of DD01 persisted after cessation of treatment. It is currently being evaluated in Phase I clinical trial to investigate the safety, tolerability, PK, and PD of DD01 administered by subcutaneous (SC) injection in overweight/obese subjects with type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD).

Explore groundbreaking therapies and clinical trials in the Obesity Pipeline. Access DelveInsight’s detailed report now! @ New Obesity Drugs

Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Obesity Products have been categorized under various ROAs such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical.

Obesity Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Unveil the future of Obesity Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Obesity Market Drivers and Barriers

Scope of the Obesity Pipeline Report

Coverage- Global
Obesity Companies- Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others.
Obesity Therapies- APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and others.
Obesity Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Obesity Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Obesity Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Obesity Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Obesity Overview
Obesity Pipeline Therapeutics
Obesity Therapeutic Assessment
Late Stage Products (Phase III)
Survodutide: Zealand Pharma
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
CT-868: Carmot Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
DD01: D&D Pharmatech
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Obesity Products
Obesity Key Companies
Obesity Key Products
Obesity Unmet Needs
Obesity Market Drivers
Obesity Market Barriers
Obesity Future Perspectives and Conclusion
Obesity Analyst Views
Obesity Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Obesity Pipeline Drugs 2024 | Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehrin

Hemato Oncology Testing Market worth $5.6 billion by 2027

“North America dominated hemato oncology testing market. The largest share can be attributed to the significant advances have been made in cancer treatment driven by advances in personalized medicine, increasing co-development projects, and increasing collaborations for developing new assay tests.”

Browse 97 market data Tables and 32 Figures spread through 145 Pages and in-depth TOC on “Hemato Oncology Testing Market by Product & Services (Services, Assay Kits), Cancer (Leukemia (Acute Myeloid, Acute Lymphocytic), Lymphoma (Non-Hodgkin, Hodgkin), Technology (PCR, NGS), End User – Global Forecast to 2027

Hemato Oncology Testing Market is projected to reach USD 5.6 billion by 2027 from an estimated USD 2.9 Billion in 2022, at a CAGR of 14.2% according to a new report by MarketsandMarkets™. The growth in this market is attributed to the growing incidence of hematologic cancer, increasing collaborations, and the increasing number of conferences on personalized medicine.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=262472877

The Services segment accounted for the largest share of the Hemato oncology testing devices market, by product type, in 2021

On the basis of products & services type, the global hemato oncology testing market is segmented into services and assay kits. The services segment accounted for the largest share of the global hemato oncology testing market in 2021. This can be attributed to the high and growing prevalence of leukemia and lymphoma.

The segment accounted for the largest share of the Hemato oncology testing devices market, by cancer type, in 2021

By cancer type, the global leukemia, lymphoma, and other cancers market. In 2021, the lymphoma segment dominated the global market. This can be attributed to factor such as the increasing prevalence and incidence of lymphoma is a major driving factor for this market.

PCR segment is anticipated to hold major share of the global Hemato oncology testing market in 2021

By technology, the global hemato oncology testing market is broadly segmented into PCR, IHC, NGS, cytogenetics, and other technologies. In 2021, the PCR segment dominated hemato oncology testing market. Factors supporting the growth of the segment is the wide use of this technology owing to its ease of use and easy availability of assay kits.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=262472877

North America to hold a significant share of the Hemato oncology testing market during the forecast period in 2021

The global hemato oncology testing market is segmented into North America, Europe, Asia Pacific, and ROW. North America dominated hemato oncology testing market. The largest share can be attributed to the significant advances have been made in cancer treatment driven by advances in personalized medicine, increasing co-development projects, and increasing collaborations for developing new assay tests.

The major players operating in the Hemato oncology testing market Abbott Laboratories (US), F. Hoffman-La Roche (Switzerland), QIAGEN (Germany), Thermo Fisher Scientific (US), Illumina (US), Bio-Rad Laboratories (US), MolecularMD (Ireland), ArcherDX (US), ARUP Laboratories (US), Asuragen (US), Invivoscribe (US), Adaptive Biotechnologies (US), Amoy Diagnostics (China), ELITechGroup (France), Vela Diagnostics (Singapore), Gentronix (UK), BioIVT (US), SAGA Diagnostics (Sweden), Olink (Sweden) and Cancer Diagnostics (US).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=262472877

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.prnewswire.com/news-releases/hemato-oncology-testing-market-worth-5-6-billion-by-2027—exclusive-report-by-marketsandmarkets-301685926.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hemato Oncology Testing Market worth $5.6 billion by 2027

Gracias Living Revolutionizes Senior Care with Groundbreaking Dementia Care Programs

Gracias Living is turning heads with its Caring approach to Senior and Assisted Living with dementia care, setting new benchmarks in the industry. The Gurgaon-based facility is garnering widespread attention for its innovative programs designed to enhance the quality of life for its residents.

Pioneering Assisted Living Services

Gracias Living is redefining assisted living with its comprehensive and personalized care solutions. The facility offers:

Tailored Assistance: Customized support plans that address individual needs, from daily activities to medical care, ensuring each resident’s unique requirements are precisely met.
Engaging Social Programs: Various social and recreational activities are designed to promote interaction and community, enhancing residents’ emotional and mental well-being.
Wellness and Health: A focus on holistic wellness, including access to on-site physiotherapy, nutritional guidance, and health monitoring to support overall health and vitality.

These initiatives reflect Gracias Living’s commitment to providing high-quality, personalized care that supports independence while ensuring safety and comfort.

Dementia Care Breakthroughs

Expanding on its assisted living services, Gracias Living has introduced groundbreaking programs specifically tailored for individuals with dementia. These include:

Advanced Memory Activities: Puzzles and memory-enhancing exercises designed to boost cognitive function.
Sensory Stimulation Techniques: State-of-the-art sensory therapies, including aromatherapy and music therapy, aimed at calming and engaging residents.
Creative Therapies: Innovative art and music therapy sessions that offer new avenues for emotional expression and mental stimulation.

These dementia-focused programs are capturing the interest of the caregiving community and setting a new standard in dementia care.

Family Support and Education

In addition to its dementia programs, Gracias Living is acclaimed for its comprehensive support for families. The facility offers specialized workshops and support groups to educate and empower caregivers, providing them with valuable tools and resources.

Enhanced Safety and Community Focus

Gracias Living’s commitment to safety and community is evident in its thoughtfully designed living spaces. The facility features secure, navigable environments with clear signage and structured daily routines, ensuring both comfort and security for its residents.

Industry Impact

The innovative practices and community-focused approach of Gracias Living are causing a stir in the senior care industry. The facility’s efforts are being recognized for their potential to transform dementia care and improve the overall quality of life for seniors.

About Gracias Living

Gracias Living is a leading senior and assisted living community in Gurgaon, dedicated to providing exceptional care and innovative solutions for its residents. For more information, visit https://graciasliving.com

Media Contact
Company Name: Gracias Living
Email: Send Email
City: Gurgaon
Country: India
Website: https://graciasliving.com/

Stéphane Bellucci Featured in Online Interview on Bmmagazine

Stéphane Bellucci, Montreal, QC, Canada

Stéphane Bellucci, President of Bellucci Ltd and a leader in the specialty coffee machine industry, has been featured in an exclusive interview with Bmmagazine, where he shares insights into his journey, the values that drive his business, and his vision for the future of the coffee industry.

In this in-depth interview, Stéphane Bellucci discusses the origins of Bellucci Ltd and how his experiences, both personal and professional, have shaped the company’s success. From his early days as a competitive swimmer in Montreal to his tenure as General Manager at Saeco Canada, Bellucci’s story is one of perseverance, innovation, and a relentless commitment to excellence.

The interview explores key aspects of Bellucci Ltd’s strategy, including the importance of innovation in staying ahead in the competitive specialty coffee machine market. Stéphane emphasizes how technological advancements and a deep understanding of customer needs have allowed Bellucci Ltd to sell and create products that resonate with true coffee enthusiasts. He also touches on the significance of balancing professional responsibilities with personal passions, such as aviation, and how this balance contributes to his success as a business leader.

Stéphane Bellucci also provides valuable advice for entrepreneurs looking to succeed in niche markets, stressing the importance of specialization, customer loyalty, and continuous innovation. He discusses the future of Bellucci Ltd in the evolving coffee industry, highlighting the company’s commitment to sustainability and its plans for expansion.

Philanthropy is another important theme in the interview. Stéphane shares how his philanthropic efforts, including supporting the Canadian Red Cross and breakfast programs for underprivileged students, align with his business values. He believes that giving back is not just about charity but about building a legacy of compassion and responsibility that complements the success of Bellucci Ltd.

About Stéphane Bellucci

Stéphane Bellucci is the President of Bellucci Ltd, a leading supplier and manufacturer of specialty espresso machines in Canada. With a career spanning decades, Stéphane has established himself as a pioneer in the coffee industry through his dedication to quality, innovation, and customer satisfaction. His journey began in Montreal , where he developed a strong work ethic as a competitive swimmer. After serving as General Manager for Saeco Canada, Stéphane founded Bellucci Ltd with his brother, where he continues to lead the company to new heights. Beyond his professional achievements, Stéphane is an aviation enthusiast and philanthropist, regularly contributing to causes close to his heart, such as the Canadian Red Cross and breakfast programs for underprivileged students.

To read the full interview, click here.

Media Contact
Contact Person: Stéphane Bellucci
Email: Send Email
City: Montreal
State: QC
Country: Canada
Website: https://www.stephanebellucci.com/

Stéphane Bellucci Featured in Exclusive Interview on IdeaMensch

Stéphane Bellucci, Montreal, QC, Canada

Stéphane Bellucci, President of Bellucci Ltd and a prominent leader in the specialty coffee machine industry, has been featured in an exclusive interview on IdeaMensch.

Stéphane Bellucci, President of Bellucci Ltd and a prominent leader in the specialty coffee machine industry, has been featured in an exclusive interview on IdeaMensch. In this insightful discussion, Stéphane shares his perspectives on leadership, innovation, and the strategies that have driven Bellucci Ltd to success.

In the interview, Stéphane Bellucci offers a glimpse into his daily routine, highlighting the importance of a structured morning to kickstart productivity. He delves into the processes that bring ideas to life at Bellucci Ltd, emphasizing the role of innovation and collaboration in creating cutting-edge espresso machines. Stéphane also discusses current trends that excite him, particularly the growing demand for sustainable products, and how Bellucci Ltd is responding to this shift with eco-friendly innovations.

The interview provides valuable advice for entrepreneurs, with Stéphane reflecting on the importance of trusting the process, embracing calculated risks, and focusing on quality over quantity. He also shares his belief in the power of listening to customers, a practice that has been instrumental in Bellucci Ltd’s customer-centric approach.

Stéphane candidly discusses a past failure in his career, offering insights into how he overcame it and the lessons learned about market research and timing. He also introduces a business idea centered around eco-friendly, compostable coffee pods — a concept aligned with his commitment to sustainability.

This interview is a must-read for anyone interested in entrepreneurship, innovation, and the specialty coffee industry.

About Stéphane Bellucci

Stéphane Bellucci is the President of Bellucci Ltd, a leading supplier and manufacturer of specialty espresso machines in Canada. With a career spanning decades, Stéphane has established himself as a pioneer in the coffee industry through his dedication to quality, innovation, and customer satisfaction. Born and raised in Montreal , where he developed a strong work ethic as a competitive swimmer, Stéphane later served as General Manager for Saeco Canada before founding Bellucci Ltd. Beyond his professional accomplishments, Stéphane is an aviation enthusiast and philanthropist, regularly contributing to causes close to his heart, such as the Canadian Red Cross and breakfast programs for underprivileged students.

To read the full interview, click here.

Media Contact
Contact Person: Stéphane Bellucci
Email: Send Email
City: Montreal
State: QC
Country: Canada
Website: https://www.stephanebellucci.com/

Axillary Hyperhidrosis Pipeline Drugs 2024 | GlaxoSmithKline, Medytox, Theravida, Candesant Biomedical

DelveInsight’s, “Axillary Hyperhidrosis Pipeline Insight 2024” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Axillary Hyperhidrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Axillary Hyperhidrosis Pipeline. Dive into DelveInsight’s comprehensive report today! @ Axillary Hyperhidrosis Pipeline Outlook

Key Takeaways from the Axillary Hyperhidrosis Pipeline Report

January 2024:- InMode MD Ltd.- The InMode radio frequency Pro System with the Morpheus8 Applicator is a computerized system generating radio frequency energy, based on the underlying technology of Fractional RF. The Morpheus8 Applicator and 24 pin tip is used for the treatment of primary hyperhidrosis of the axillae.
DelveInsight’s Axillary Hyperhidrosis pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Axillary Hyperhidrosis treatment.
The leading Axillary Hyperhidrosis Companies such as GlaxoSmithKline, Medytox, Theravida, Candesant Biomedical, and others.
Promising Axillary Hyperhidrosis Therapies such as Sofpironium bromide, ET-01, DMT410, and others.

Stay ahead with the most recent pipeline outlook for Axillary Hyperhidrosis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Axillary Hyperhidrosis Treatment Drugs

Axillary Hyperhidrosis Emerging Drugs

Sofpironium bromide: Brickell Biotech Inc.

Sofpironium bromide is a new chemical entity that we are currently developing in the U.S. as a potential best-in-class, self-administered, once-daily, topical therapy for the treatment of primary axillary hyperhidrosis, or excessive underarm sweating. The drug is a retro metabolically designed anticholinergic agent which selectively binds to M3 AC receptor potentially inhibiting sweat production.

ET-01: Eirion Therapeutics

ET-01 is a topical botulinum product being developed with the goal of avoiding the pain, bleeding and bruising that can be associated with the injection of commercially available botulinum products. ET-01 employs a nanoemulsion transdermal delivery technology essential for a large molecule such as botulinum to penetrate into the skin.The drug is currently being developed in Phase 2 stage of development for the treatment of Axillary Hyperhidrosis.

DMT410: Dermata Therapeutics LLC pipeline

DMT410 is the second development program using DMT400 combination regimen in combination with botulinum toxin. Dermata Therapeutics have completed a proof of concept, Phase 1 clinical trial using DMT410 in combination with BOTOX® for the treatment of primary axillary hyperhidrosis. The treatment was well tolerated, and a majority of patients saw a reduction in sweat production similar to results seen from using injections of BOTOX®.

Explore groundbreaking therapies and clinical trials in the Axillary Hyperhidrosis Pipeline. Access DelveInsight’s detailed report now! @ New Axillary Hyperhidrosis Drugs

Axillary Hyperhidrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Axillary Hyperhidrosis Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule

Unveil the future of Axillary Hyperhidrosis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Axillary Hyperhidrosis Market Drivers and Barriers

Scope of the Axillary Hyperhidrosis Pipeline Report

Coverage- Global
Axillary Hyperhidrosis Companies- GlaxoSmithKline, Medytox, Theravida, Candesant Biomedical, and others.
Axillary Hyperhidrosis Therapies- Sofpironium bromide, ET-01, DMT410, and others.
Axillary Hyperhidrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Axillary Hyperhidrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Axillary Hyperhidrosis Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Axillary Hyperhidrosis Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Axillary Hyperhidrosis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Axillary Hyperhidrosis– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Sofpironium bromide: Brickell Biotech Inc
Drug profiles in the detailed report…..
Last Stage Products (Phase III)
Drug Name: Company Name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
ET-01: Eirion Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Axillary Hyperhidrosis Key Companies
Axillary Hyperhidrosis Key Products
Axillary Hyperhidrosis – Unmet Needs
Axillary Hyperhidrosis – Market Drivers and Barriers
Axillary Hyperhidrosis – Future Perspectives and Conclusion
Axillary Hyperhidrosis Analyst Views
Axillary Hyperhidrosis Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Axillary Hyperhidrosis Pipeline Drugs 2024 | GlaxoSmithKline, Medytox, Theravida, Candesant Biomedical

Peraso Inc.’s (NASDAQ: PRSO) PERSPECTUS Modules Outperform in 60Ghz FWA Market

Introduction

As high-speed internet access spreads around the world, the unlicensed 60GHz (57-71 Ghz) millimeter-wave (mmWave) spectrum offers immense potential for low-cost, low-capex, easily-deployed high-speed wireless communication, especially areas currently underserved by traditional broadband distribution—fiberoptic. Further, However, until recently, purchasing devices to adequately provide mmWave communications for 60Ghz/mmWave broadband deployments has been difficult. Peraso and several other companies have developed and ramped up mass manufacturing of viable 60Ghz solutions for this market, which is further set to grow as other frequency bands, such as those used by WiFi (2.4 and 5Ghz) and 4G cellular, become more and more saturated and congested.

In contrast, 60Ghz mmWave has almost unlimited potential as it does not penetrate objects extremely well, and it attenuates more, and can be directionalized more effectively using phased arrays. As such, “Fixed 5G,” 60Ghz/mmWave, also referred to as unlicensed V-band, is an excellent option for high-capacity backhaul; for instance, a narrow 60Ghz over-the-air beam instead of fiber optic cable.

Looking at several competing products as potential selections for 60Ghz FWA buildouts in lieu of fiber, Peraso’s PERSPECTUS product line appears to best capitalize on this opportunity, for both dense urban environments and rural areas. Peraso’s technology and products are positioned for success in these distinct contexts.

60Ghz mmWave for Broadband: Feasible, but Difficult

The unlicensed 60Ghz V-band provides abundant bandwidth withthe largest amount of contiguous spectrum available, enabling gigabit-per-second data rates. mmWave was originally envisioned for indoor use only due to line-of-sight constraints and oxygen’s absorption-causing attenuation in the middle of the 57-71Ghz spectrum, right around 60Ghz. While 60GHz signals attenuate rapidly over distance, this limitation can be an asset in certain situations. Short-range, high-speed connections are ideal for applications like home broadband, office networks, and IoT deployments. However, Peraso has out-innovated its peers; its chipsets and integrated modules (containing antenna) enable point-to-point (PtP) distances of up to 20km (~12.5mi). This was done with several engineering efforts, from proprietary advanced beamforming techniques to employing the entire unlicensed V-band (57-71Ghz) to “work around” the oxygen attenuated range. Other suppliers do not use the V-band from 57Ghz all the way up to 71Ghz as it is difficult to produce chips to support the 66-71Ghz band with reliability and low variance—a capacity Peraso has honed with years of experience.

Other challenges with mmWave include line-of-sight challenges. Obstacles can significantly

attenuate signal strength. This includes walls, but also foliage, which may grow and change

shape to interfere with signaling after a fixed wireless link is deployed. Peraso’s products are

designed to handle these in-field practical problems as they have adaptive beamforming, where the technology dynamically adjusts beam direction, compensating for obstacles and maintaining optimized connectivity. Additionally, in dense urban areas, line-of-sight paths are often obstructed before deployment. Peraso’s PERSPECTUS modules mitigate this by exploiting the signal’s reflections and diffractions, ensuring robust connections, even around corners.

Lucrative Applications for 60Ghz mmWave

In both dense urban environments as well as rural areas, oftentimes cost of deploying a network is a limiting factor in bringing broadband online for these communities.

Concerning rural areas, the cost of FWA in an example area has been estimated to be about 10% of the upfront cost and 30% of the total long-term cost compared with fiber in the same area. Other non-rural estimates place the total capex at 50-60% of fiber’s capex, which is still less expensive. One downside of FWA is the higher cost of power compared to fiber; however, Peraso’s units have superior cost and energy performance profiles with low wattage and optimized beamforming, resulting in more efficient power transmission.

With respect to dense urban environments, the 60Ghz value proposition is somewhat different. Of course, cost and performance are always important; however, in dense urban environments, the main proposition is the high data speeds and the lack of interference and congestion that can be accomplished with 60Ghz. Peraso, specifically, has also powered its FWA offering with an internet protocol called DUNE which improves the distribution of data communication to large numbers of users in a congested area, by optimizing the structure of data sent. This dynamic traffic management improves PtMP network capacity by up to almost 50% with low (1-4ms) latency. And Peraso’s up-to-32 user APs, connected to Peraso’s PtMP location, can be backhauled efficiently with Peraso’s PtP solution. In each situation (rural, urban), access points can be added as user demand grows.

60Ghz mmWave: Market Leadership

Peraso recently announced its first purchase order for its DUNE-powered PERSPECTUS solution, whereby the PERSPECTUS modules will be used in conjunction with DUNE to supply mmWave connectivity for informal settlements. FWA leader Ubituiti, along with other FWA suppliers, appears to prefer Peraso’s technology for its FWA solutions, and when looking at PERSPECTUS specifications and roughly comparing to competitors, it is clear why.

Company	Peraso/Ubiquiti		Siklu/Ceragon		Ignitenet

			PtP

*Product*		Wave Pro		EtherHaul 600/614		MLTG-CN LR

Total User Capacity		5.4 Gbps		1 Gbps		3.6 Gbps

Range		15 km		2.6 km			1 km

Antenna Gain	46			36 dBi			40 dBi

Frequency Band	57-71 GHz		57-68 GHz			57-66 GHz

Power Consumption	26 W max		26 W			15.9 W max

			PtMP

*Product*		Wave Pro			MultiHaul B100		MLTG-360-1

# STA	24		8		15

Total User Capacity		5.4 Gbps		2.3 Gbps			3.8 Gbps

Range		8 km		400 m			300 m

Gain		46 dBi		40 dBi			28 dBi

Frequency Band	57-71 GHz		57-64 GHz			57-66 GHz

Power Consumption	26 W max		10 W			30 W max

Watts/max STA	1.08		1.25		2

The last thing to note is that specifications are not the end-all-be-all. How well the products work in the field—their practicality and reliability—and the products’ economics are the most important factors for FWA hardware selection. Several 60Ghz competitors have fallen victim to Peraso’s superior competitiveness in the 60Ghz FWA market, and in-field success is likely a big part of that commercial success. While there are other bands available to provide connectivity, as those bands become congested, saturated, or struggle with interference, its likely that more will turn to the interference-free 60Ghz mmWave market as a solution, where Peraso leads, especially with greatly superior PtP (backhaul) and PtMP distances and overall reliability.

Conclusion

Peraso’s PERSPECTUS modules are poised for success in the 60GHz mmWave market. Their adaptability, speed, and versatility make them indispensable for both urban and rural connectivity. Even to non-RF engineers, it should be clear why Peraso is the market leader Ubituiti’s supplier-of-choice for 60Ghz solutions.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Peraso Inc.\’s (NASDAQ: PRSO) PERSPECTUS Modules Outperform in 60Ghz FWA Market

Smart Grid Storage Technologies Market 2024: Emerging Trends, Growth Opportunities, and Key Players

“Smart Grid Storage Technologies Market”

Smart Grid Storage Technologies Market is expected to expand with a CAGR of 11.73% during the forecast period of 2024-2031.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Smart Grid Storage Technologies Market Size, Share & Trends Analysis Report By Types (Lead-Acid Storage Technologies, Sulphur Storage Technologies, Lithium-Ion Storage Technologies, Supercapacitors Storage Technologies, Flow Wheel Storage Technologies, Other), By Applications (Power Utilities, Independent Power Producers (IPPs), Other)- Market Outlook And Industry Analysis 2031″

The Global Smart Grid Storage Technologies Market is expected to expand with a CAGR of 11.73% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC : https://www.insightaceanalytic.com/request-sample/2626

Smart Grid Storage Technologies refer to energy storage solutions integrated into smart grid systems to enhance efficiency, reliability, and flexibility. These technologies store electrical energy for later use, better managing supply and demand fluctuations. Key applications include integrating intermittent renewable energy sources like solar and wind by storing excess energy during high generation and releasing it during low generation. They also enable peak shaving and load leveling by storing energy during off-peak hours and discharging it during peak hours, provide frequency regulation services to maintain grid stability, and offer backup power to critical infrastructure and consumers during outages, improving grid reliability.

The significance of Smart Grid Storage Technologies is growing due to the increasing integration of renewable energy, which necessitates managing the intermittent and variability of these sources. They also address the challenges of aging grid infrastructure by offering a cost-effective alternative to building new transmission and distribution lines. Additionally, energy storage improves grid efficiency and reliability by reducing losses, providing backup power, and enabling better management of supply and demand. These technologies are fostering new business models in the energy sector, such as energy arbitrage, demand response, and ancillary services.

List of Prominent Players in the Smart Grid Storage Technologies Market:

ABB Ltd
Altairnano
Beacon Power
GE Energy Storage
Highview Power Storage
Ice Energy
Itron
PolyPlus Battery Company
Samsung SDI Energy
Schneider Electric
Siemens
Sumitomo
Xtreme Power
AES Corporation
Tesla, Inc.
Saft Groupe S.A.
LG Chem Ltd.
BYD Company Limited

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2024-02

Market Dynamics:

Drivers-

The increasing adoption of renewable energy sources like solar and wind is driving the need for energy storage solutions to manage their intermittent and variability. Government policies and utility investments in grid modernization and smart grid infrastructure are also fueling demand for these technologies. Energy storage enhances grid efficiency and reliability by reducing losses, providing backup power, and enabling better management of supply and demand, making it an attractive option for utilities. Additionally, Smart Grid Storage Technologies are enabling new business models such as energy arbitrage, demand response, and ancillary services, driving market growth. The declining costs of energy storage technologies, particularly batteries, further enhance their accessibility and cost-effectiveness for grid applications.

Challenges:

High initial costs for smart grid storage technologies, particularly advanced batteries, can deter potential adopters. Technological limitations, such as energy density, cycle life, and environmental impact of current storage solutions like lithium-ion batteries, affect their long-term viability. Additionally, inconsistent regulations and policies across regions create uncertainty for investors and hinder the deployment of smart grid storage solutions.

Regional Trends:

North America leads the Smart Grid Storage Technologies market with advancements in smart metering, distribution automation, and grid optimization, enhancing operational efficiency and reliability. Strong government support and regulatory frameworks promote clean energy and grid modernization, driving investment in storage solutions. Increased collaboration between utilities and technology providers fosters innovation and deployment of advanced storage technologies. Additionally, a focus on grid resilience and cybersecurity addresses climate change and security challenges, with smart grid storage playing a key role in maintaining service continuity and enhancing system reliability.

Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/enquiry-before-buying/2626

Recent Developments:

In June 2024, Highview Power secured £300m ($383m) for its first commercial-scale liquid air energy storage (LAES) plant in Carrington, Manchester. The investment, led by the UK Infrastructure Bank and Centrica, will support the construction of one of the world’s largest long-duration energy storage facilities.
In Feb 2024, Itron, Inc. and Schneider Electric are collaborating to enhance energy and grid management as distributed energy resources (DERs) like solar, battery storage, and electric vehicles become more common. They will integrate their intelligent grid and DER management solutions to digitalize electricity demand and supply.
In April 2024, Schneider Electric launched a new Battery Energy Storage System (BESS) designed for flexible and scalable architecture. This BESS forms the core of a fully integrated microgrid solution, supported by Schneider Electric’s controls, optimization, electrical distribution, and renowned digital and field services.

Segmentation of Smart Grid Storage Technologies Market-

By Types:

Lead-Acid Storage Technologies
Sulphur Storage Technologies
Lithium-Ion Storage Technologies
Supercapacitors Storage Technologies
Flow Wheel Storage Technologies
Other

By Applications:

Power Utilities
Independent Power Producers (IPPs)
Other

By Region-

North America-

The US
Canada
Mexico

Europe-

Germany
The UK
France
Italy
Spain
Rest of Europe

Asia-Pacific-

China
Japan
India
South Korea
South East Asia
Rest of Asia Pacific

Latin America-

Brazil
Argentina
Rest of Latin America

Middle East & Africa-

GCC Countries
South Africa
Rest of Middle East and Africa

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2626

About Us:

Media Contact
Company Name: InsightAce Analytic Pvt. Ltd
Contact Person: Diana D’Souza
Email: Send Email
Country: United States
Website: https://www.insightaceanalytic.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Smart Grid Storage Technologies Market 2024: Emerging Trends, Growth Opportunities, and Key Players

Pinnacle of Glory, Global Consensus Ignited: SMiC Mount Fuji Partner Program Strongly Unveils

This is an exhilarating moment! SMiC is declaring with unstoppable momentum that the new era of global DAO has officially begun! As a benchmark for global DAO, our mission is to lead global partners to the pinnacle of wealth, and our vision is to surpass Bitcoin in consensus of digital credentials! Now, the SMiC Mount Fuji Partner Program is about to launch, and this unprecedented event will ignite the passion of the global SMiC market, starting a magnificent journey of co-creating a wealth legend!

Mount Fuji Partner Program: Uniting Global Top Talent to Create a Brilliant Future!

In August, all eyes of SMiC are on Tokyo! This is a historic moment not to be missed. SMiC extends a warm invitation to all partners with two-star status and above: join us in climbing Mount Fuji to experience its magnificent scenery and boundless inspiration! Mount Fuji is not just a peak, but a launching pad for the global SMiC career and a new starting point for our collective journey towards a grand vision!

SMiC has meticulously planned and crafted a luxurious journey to Japan: direct flights to Tokyo from around the world, top-notch accommodation in five-star hotels, and attentive reception services—every detail has been finely tuned to ensure that each SMiC partner enjoys the highest level of experience! This is not just a trip but a grand feast of business wisdom! SMiC has also extended a special invitation to local Japanese business leaders and political elites to join global SMiC partners in discussing the future. This will be a pinnacle event of brainstorming and intellectual exchange!

The Mount Fuji Partner Program symbolizes SMiC’s global leadership and is a crucial step towards achieving our vision of surpassing Bitcoin. This summer, SMiC will join hands with global partners at the summit of Mount Fuji to embark on a new chapter in our great career!

Global Mobilization: The Mount Fuji Partner Program Ignites the Market, Showcasing SMiC’s Ironclad Execution!

On August 26th, the core leadership team of SMiC will arrive in Japan to witness this epic summit event alongside global SMiC business partners! This is not just a trip but a global celebration of the SMiC career! The Mount Fuji Partner Program has become the focus of the global market, with all two-star and above partners gathering to ignite the market frenzy of August!

In order to climb Mount Fuji and walk alongside SMiC’s visionary leaders, global SMiC partners are giving their all with a clear goal—upgrading! Becoming a two-star partner to earn a spot in this pinnacle journey! The call to action from SMiC has reverberated around the world, and our partners are breaking through self-imposed limits at an astonishing pace, advancing from one-star to two-star, demonstrating an ironclad execution akin to a military force!

SMiC leaders excitedly stated: “We will witness the gathering of the world’s top business partners in Tokyo! With everyone’s dedication and drive, SMiC will undoubtedly spark an unstoppable wave of career across the globe. We firmly believe that with faith, motivation, and results, SMIC’s career will soar and sweep the world!”

Summit of Mount Fuji: Smile, Move, Integrity, Collaboration — SMiC’s Super IP Sparks Global Resonance!

Mount Fuji, a peak symbolizing the spirit of Japan, carries the history of a nation’s rise to glory. Now, SMiC’s core leadership team will lead global two-star and above partners to climb this pinnacle of faith and strength! This is not just a climb but a spiritual journey, a peak moment for us to forge a global consensus together! Here, SMiC will embody the values of “Smile, Action, Integrity, and Win-Win,” transforming Mount Fuji into a symbol of our global career!

On August 26, 2024, the world will witness the magnificent launch of the SMiC Mount Fuji Partner Program! With a pilgrim’s heart, global SMiC partners, guided by our leaders, will ascend the summit of Mount Fuji, embarking on the great journey of the SMiC career! Because we face challenges with a smile, act decisively, uphold integrity, and believe in cooperation and mutual benefit—SMiC is crafting a Wealthy Mount Fuji for billions of ordinary people around the world! The SMiC career is unstoppable, and the brilliance has already begun!

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: SMiC Matrix
Contact Person: Donald C. Brown
Email: Send Email
Country: Singapore
Website: www.smicmatrix.com